Product Images Kazano

This is a study of the effectiveness of different drugs, including placebo, alogliptin, metformin, and a combination of alogliptin and metformin. The baseline was measured at 85 for most drugs. The study was conducted on patients who discontinued the double-blind study medication or needed rescue with sulfonylurea therapy. The results of the study showed that the combination of alogliptin and metformin was more effective than either drug alone or the placebo. The difference was statistically significant with a P-value of less than 0.001.*

This is a medication label that contains important information about dosage, ingredients, and storage instructions. It also includes a cautionary statement to keep the medication out of reach of children and a warning to not accept the medication if the seal over the battery is broken or missing. The medication in question is a combination tablet that contains alogliptin benzoate and metformin HCI for the treatment of a medical condition that is not specified in the text. The label advises storing the medication at room temperature and dispensing it in a tightly closed container.*

Kazano tablets are a medicine with a usual dosage of one pack per time. They contain 17mg of clogliptn benzocate equivalent, which is equivalent to 10,125mg of dlogliptn and 1000mg mefiomin KO. The bottle itself should be kept out of reach of children due to the missing or broken opener. These tablets should be stored between 15 and 30 degrees Celsius, and in a tightly closed container at room temperature. Dispensing should include the medication guide. Distributed by Takeda Pharmaceuticals America inc, located in Lexington, Massachusetts with product # NDC 64764-337-60.*